Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018

Publisher Name :
Date: 01-Mar-2018
No. of pages: 2000
Inquire Before Buying

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2012 to 2018.

There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology.

There are several forms of a collaborative R&D deal; A traditional collaborative R&D arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subscequent sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful period of collaborative R&D on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the collaborative R&D agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to comoercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all collaborative R&D deals announced since 2012 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading collaborative R&D deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a review of the top 50 most active biopharma companies in collaborative R&D. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a comprehensive review of collaborative R&D financials for deals announced since 2012, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.

Chapter 7 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2012 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2012.

In addition, a comprehensive appendix is provided organized by company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D partnering in the research, development and commercialization of technologies and products.

Key benefits

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 provides the reader with the following key benefits:

In-depth understanding of collaborative R&D deal trends since 2012

Analysis of the structure of collaborative R&D agreements with numerous real life case studies

Comprehensive listing of over 4,500 collaborative R&D deals since 2012, together with deal terms, value and press release

Comprehensive access to actual collaborative R&D contracts entered into by the world's life science companies

Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates

Insight into the terms included in a collaborative R&D agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 is intended to provide the reader with an in-depth understanding of the collaborative R&D trends and structure of deals entered into by leading life science companies worldwide.

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 includes:

Trends in collaborative R&D dealmaking in the biopharma industry since 2012

Analysis of collaborative R&D deal structure

Case studies of real-life collaborative R&D deals

Comprehensive listing of over 4,500 collaborative R&D deals since 2012

Access to collaborative R&D contract documents

Key financial benchmarks for headline, upfront, milestone and royalty rates

The leading collaborative R&D deals by value since 2012

Most active collaborative R&D dealmakers since 2012

The leading collaborative R&D partnering resources

In Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 available deals and contracts are listed by:

Company A-Z

Headline value

Therapeutic area

Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How do milestone align with clinical stage development phases?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in collaborative R&D dealmaking
2.1. Introduction
2.2. Definition of collaborative R&D partnering
2.3. Success factors for collaborative R&D deals
2.4. When collaborative R&D can be useful
2.5. Attributes of collaborative R&D deals
2.6. Trends in collaborative R&D deals since 2012
2.6.1. Collaborative R&D dealmaking by year, 2012 to 2018
2.6.2. Collaborative R&D dealmaking by phase of development, 2012 to 2018
2.6.3. Collaborative R&D dealmaking by industry sector, 2012 to 2018
2.6.4. Collaborative R&D dealmaking by therapy area, 2012 to 2018
2.6.5. Collaborative R&D dealmaking by technology type, 2012 to 2018
2.6.6. Collaborative R&D dealmaking by most active company, 2012 to 2018
2.7. The future of collaborative R&D deals

Chapter 3 - Overview of collaborative R&D deal structure
3.1. Introduction
3.2. Pure versus multi-component collaborative R&D deals
3.3. Pure collaborative R&D agreement structure
3.3.1. Example collaborative R&D agreements
3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica
3.3.1.b. Case study 2: Idenix Pharmaceuticals - Janssen Pharmaceuticals
3.4. Collaborative R&D as part of a wider alliance agreement
3.4.1. Example collaborative R&D agreements and their licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics - UniQure
3.4.1.b. Case study 4: Kyowa Hakko Kirin - Ultragenyx Pharmaceuticals
3.4.2. Example licensing option right clauses in collaborative R&D deals
3.4.2.a. Case study 5: Forest Laboratories - Trevena
3.4.2.b. Case study 6: Abbvie - Receptos

Chapter 4 - Leading collaborative R&D deals
4.1. Introduction
4.2. Top collaborative R&D deals by value

Chapter 5 - Top 50 most active collaborative R&D dealmakers
5.1. Introduction
5.2. Top 50 most active collaborative R&D dealmakers

Chapter 6 - Collaborative R&D deal term financials
6.1. Introduction
6.2. Collaborative R&D partnering headline values
6.3. Collaborative R&D deal upfront payments
6.4. Collaborative R&D deal milestone payments
6.5. Collaborative R&D royalty rates

Chapter 7 - Collaborative R&D contract directory 2012 - 2018
7.1. Introduction
7.2. Collaborative R&D deals with contracts 2012 to 2018

Appendices
Appendix 1 - Collaborative R&D dealmaking by companies A-Z
Appendix 2 - Collaborative R&D dealmaking by industry sector
Appendix 3 - Collaborative R&D dealmaking by stage of development
Appendix 4 - Collaborative R&D dealmaking by therapy area
Appendix 5 - Collaborative R&D dealmaking by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Definition of collaborative R&D
Figure 2: Situations where collaborative R&D can prove useful
Figure 3: Key attributes of a collaborative R&D deal
Figure 4: Trends in Collaborative R&D deal announcements, 2012 to 2018
Figure 5: Collaborative R&D deals signed at each phase of development, 2012 to 2018
Figure 6: Collaborative R&D deals by industry sector, 2012 to 2018
Figure 7: Collaborative R&D deals by therapy area, 2012 to 2018
Figure 8: Collaborative R&D deals by technology type, 2012 to 2018
Figure 9: Top 50 most active collaborative R&D dealmakers, 2012 to 2018
Figure 10: Collaborative R&D agreements - what should a contract include?
Figure 11: Components of the collaborative R&D deal structure
Figure 12: Top collaborative deals by value 2012 to 2018
Figure 13: Most active collaborative R&D dealmakers 2012 to 2018
Figure 14: Collaborative R&D deals with a headline value
Figure 15: Collaborative R&D deals with an upfront value
Figure 16: Collaborative R&D deals with a milestone value
Figure 17: Collaborative R&D deals with a royalty rate value
  • Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2018
    Published: 01-May-2018        Price: US 2995 Onwards        Pages: 2500
    Summary The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012- 2018 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of licensing agree......
  • Global Big Pharma Partnering Terms and Agreements 2012-2018: Deal trends, players and financials
    Published: 01-Apr-2018        Price: US 2995 Onwards        Pages: 1000
    Global Big Pharma Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Big Pharma agreements announced in the life sciences since 2012. The report takes the reader through a comprehensive review Big Phar......
  • Global Academic and Non-Profit Partnering Terms and Agreements 2012-2018: Deal trends, players and financials
    Published: 01-Apr-2018        Price: US 2995 Onwards        Pages: 1000
    "Delivery of this report will take 1-3 days after purchase." Summary Global Academic and Non-Profit Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Academic ......
  • Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018
    Published: 01-Apr-2018        Price: US 2995 Onwards        Pages: 1000
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, diagnostic and other lifescience sectors. Fully revised and updated, the report provides details of M&A agreements from 2012 to 2018. The report pr......
  • Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018
    Published: 01-Mar-2018        Price: US 2995 Onwards        Pages: 344
    The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, t......
  • Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
    Published: 01-Mar-2018        Price: US 1995 Onwards        Pages: 350
    The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies. The report provides a detailed understanding and analysis of how and why companies enter business, royalty financing agreements. The focus of the report is on partnerships for royalty assets where partne......
  • Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018
    Published: 01-Mar-2018        Price: US 1995 Onwards        Pages: 348
    The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements ......
  • Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012 to 2018
    Published: 01-Mar-2018        Price: US 2995 Onwards        Pages: 457
    The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest Co-development agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of Co-developmen......
  • Partnerships, Licensing, Investments and M&A Deals and Trends for November 2017 in Pharmaceuticals
    Published: 02-Jan-2018        Price: US 1000 Onwards        Pages: 77
    Partnerships, Licensing, Investments and M&A Deals and Trends for November 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for November 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions,......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs